Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 13, Issue 1, Pages 1-8Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.2012.638283
Keywords
contraindications; diabetes mellitus; heart failure; metformin; oral hypoglycaemic agents
Categories
Ask authors/readers for more resources
Metformin represents the cornerstone of treatment for type 2 diabetes mellitus. Traditionally, heart failure (HF) was considered a contraindication to its use. However, more recent evidence has shown that this should no longer be the case. Indeed, studies have demonstrated that metformin may even reduce the risk of incident HF and mortality in diabetic patients, while improving up to 2-year survival rates in those with HF. In addition, it appears to exert cardioprotective actions. Although longer follow-up data and more explicit information about the situation in patients with very advanced HF are needed, the cardiac safety of metformin has profound clinical implications and may be anticipated to further encourage its widespread use.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available